Turn this list into pipeline.
Pharmaceutical Companies in Portsmouth: 43 Active Firms (2026)
Pharmaceutical companies in Portsmouth develop, manufacture or distribute regulated medicines for healthcare markets across the surrounding metro area.
Buying centres tend to sit in quality assurance, clinical supply, medicine distribution and regulatory affairs rather than broad consumer healthcare. Buyers are usually procurement, pharmacy, clinical operations or supply-chain teams that need evidence of licence coverage, batch traceability and process control before commercial discussions move far. The more relevant Portsmouth targets are small and lower mid-market operators, often selling into healthcare providers, wholesalers and life-sciences supply chains. Engagements are rarely light-touch software-style purchases; they tend to involve qualification work, audit packs, technical documentation and ongoing compliance obligations.
Read more
Portsmouth has 43 actively trading pharmaceutical companies, giving the local market the feel of a specialised metro cluster rather than a national manufacturing base. Reported headcount across this cohort totals 36 people, which points to a market weighted towards owner-managed specialists, local distribution roles and small regulated operations. For researchers, that matters because revenue and licence status are likely to be more informative than headcount alone: a compact team can still handle valuable clinical-supply, import, quality or wholesale activity if the relevant permissions and inspection history are in place.
Human medicines activity around Portsmouth sits under MHRA oversight, with different obligations depending on whether a business manufactures, assembles, imports, markets or distributes medicines. GOV.UK guidance requires a manufacturer’s licence for making, assembling or importing human medicines, with compliance assessed against good manufacturing practice and regular site inspections. Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance. Medicines also need marketing authorisation, while publicly funded prescribing access brings cost-effectiveness scrutiny. The ABPI remains the main trade body reference point for research-based pharmaceutical businesses.
Future demand appears likely to favour firms that can evidence compliance as much as technical capability. Portsmouth’s cohort looks oriented towards specialist supply-chain, distribution and regulated service roles, so consolidation may be more common than large standalone manufacturing expansion. Smaller operators tend to face rising documentation, pharmacovigilance and audit expectations, which can push them towards partnerships with larger licence holders or contract networks. The better-positioned firms are likely to be those with defensible quality systems, repeat clinical or wholesale relationships, and enough regulatory capacity to absorb inspection cycles without slowing day-to-day supply work.
43
Active firms
2026
2
Above £5M
Reported revenue
15
Incorporated since 2022
Portsmouth cohort
Key facts
About 4% of the trading cohort reports turnover above £5M (2 of 43 firms) — the rest sits below that revenue band.
34% of the cohort was incorporated since 2022 (15 firms), so a sizeable share is in its first few filing cycles.
The MHRA regulates UK human medicines, including standards, clinical trial approvals, medicines licensing and pharmacovigilance.
Organisations that make, assemble or import human medicines need an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
UK businesses performed £9.0 billion of pharmaceutical R&D in 2022, equivalent to 0.36% of UK GDP and 18% of all UK business R&D.
UK pharmaceutical exports were valued at £25.6 billion in 2023, with the UK ranked tenth among comparator countries for this metric.
Medicines require a marketing authorisation, and NHS access can add cost-effectiveness review by bodies such as NICE.
Top Portsmouth Pharmaceutical companies
Navitas Life Sciences Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services to pharmaceutical, biotechnology and medical device organisations, including clinical trial management, bioavailability and bioequivalence studies, regulatory…
Serves global pharma, biotech and medical device sponsors, plus government agencies and non-profits involved in clinical development, regulatory, pharmacovigilance and post-market programmes.
Financial Health
HealthyHealthy · Hiring · 11% CAGR over 4y
Location
Navitas Life Sciences Holdings Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services to pharmaceutical and biotechnology companies, including clinical trial management, bioavailability and bioequivalence studies, regulatory affairs support,…
Serves pharmaceutical, biotech and medical device sponsors worldwide, plus government health agencies and non-profit foundations involved in clinical development, regulatory, pharmacovigilance, data…
Financial Health
StrongStrong
Location
Nitespharma Uk Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies and brokers pharmaceutical products, linking manufacturers and buyers. Distributes OTC, generic and branded medicines sourced from approved UK and EU facilities, and supplies unlicensed…
Serves pharmaceutical buyers and suppliers, pharmacies and healthcare businesses seeking OTC, generic, branded and unlicensed medicines, plus UK consumers buying beauty, personal care and children’s…
Financial Health
StableStable · -7% CAGR over 4y
Location
Aura Fragrances Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · 0% CAGR over 4y
Location
EKA Clinical Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak · 0% CAGR over 2y
Location
EMRA CONSULT LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
MENG & WING LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StrongStrong
Location
Wickham Micro
Provides contract microbiology testing for pharmaceutical products and medical devices. Services include sterility, bioburden, endotoxin and antimicrobial efficacy testing, method validation,…
Serves pharmaceutical and medical device companies worldwide, including manufacturers and development teams needing microbiology testing support from early-stage development through product release…
Financial Health
Insufficient historyInsufficient history
Location
Unlock all 43 leads
Showing 8 of 43 — +35 more with verified decision-maker contacts, live data, and CRM sync.
How Portsmouth Pharmaceutical companies work and how to sell to them
What they do
Revenue usually comes from regulated supply rather than consumer brand marketing: medicine wholesale margins, contract assembly fees, import handling, batch-release support, clinical-supply services and recurring quality or regulatory retainers. Engagements are commonly priced by batch, product line, shipment lane, licence scope or service package, with repeat work where a customer depends on the same quality system or distribution route. The commercial product is rarely just the medicine or component itself; it is the physical supply activity plus documentation, traceability, storage controls, release evidence and named regulatory responsibility.
Who they sell to
Typical buyers include healthcare providers, pharmacy groups, wholesalers, clinical-trial sponsors, contract research teams and life-sciences manufacturers that need local supply or licensed handling capacity. Decision-makers tend to sit in procurement, pharmacy, quality, clinical operations, supply chain and regulatory affairs, with finance involved once repeat spend is clear. Contract values are usually operational rather than enterprise-wide, though a small number of Portsmouth operators have already passed £5M revenue, so account potential varies. Sales cycles are usually measured in weeks or months because supplier qualification, licence checks and audit responses sit ahead of price negotiation.
What they buy
Most Portsmouth pharmaceutical firms tend to spend on systems and services that protect traceability, audit readiness and controlled supply. Relevant categories include quality management, document control, batch records, supplier qualification, pharmacovigilance workflow, inventory management, warehouse controls, temperature monitoring, finance, payroll and HR. They also buy specialist legal, accounting, insurance, validation, recruitment and regulatory consulting support, particularly when licences, inspections or customer audits are in play. Infrastructure spend may include secure cloud hosting, access control, backup, cyber security, laboratory or warehouse equipment, and facilities services where storage conditions or segregation requirements matter.
Why and how to sell to them
Buying triggers tend to appear when firms apply for or vary an MHRA licence, add a distribution route, win a clinical or wholesale account, appoint a quality lead, move premises, or face a customer audit. Pain points are practical: inspection preparation, batch traceability, document version control, supplier evidence, temperature excursions, delayed release and duplicated manual work. Sellers usually get further with proof that their category reduces audit burden, shortens qualification work or helps protect continuity of supply. Generic productivity messaging is less persuasive than a clear link to good manufacturing practice, good distribution practice or pharmacovigilance obligations.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Portsmouth
Related directories
Frequently asked questions
How many pharmaceutical companies are there in Portsmouth?
What counts as a pharmaceutical company in this list?
Which are the largest pharmaceutical companies in Portsmouth?
What do pharmaceutical companies in Portsmouth actually do?
How does Portsmouth pharmaceutical compare internationally?
How is this list built and how fresh is the data?
How big are the typical pharmaceutical companies in Portsmouth?
Are these mostly new or established pharmaceutical companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 43 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.